Group 1 - Hong Kong pharmaceutical and medical concept stocks declined, with Kangfang Biotech and MicroPort Medical dropping over 4%, Ping An Good Doctor down over 3%, and WuXi Biologics, WuXi AppTec, and CSPC Pharmaceutical falling over 2% [1] - Multiple Hong Kong medical and innovative drug-related ETFs fell by more than 2% due to market influences [1] Group 2 - Analysis indicates that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with procurement amounts from January to May nearing the total for the entire year of 2024, demonstrating the competitiveness of China's innovative drugs in the international market [2] - The trend of large multinational pharmaceutical companies accelerating the procurement of innovative drug patents from China is expected to continue in the medium to long term [2]
港股医药、医疗概念股走低，相关ETF跌超2%
Sou Hu Cai Jing·2025-08-04 02:41